0001437749-23-013121.txt : 20230508
0001437749-23-013121.hdr.sgml : 20230508
20230508214443
ACCESSION NUMBER: 0001437749-23-013121
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230503
FILED AS OF DATE: 20230508
DATE AS OF CHANGE: 20230508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bode John B
CENTRAL INDEX KEY: 0001612084
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36913
FILM NUMBER: 23899715
MAIL ADDRESS:
STREET 1: C/O TRIBUNE PUBLISHING COMPANY
STREET 2: 202 W. FIRST STREET
CITY: LOS ANGELES
STATE: CA
ZIP: 90012
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZEVRA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001434647
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205894398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
BUSINESS PHONE: (321) 939-3416
MAIL ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM, INC
DATE OF NAME CHANGE: 20130530
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM INC
DATE OF NAME CHANGE: 20080507
4
1
rdgdoc.xml
FORM 4
X0407
4
2023-05-03
0001434647
ZEVRA THERAPEUTICS, INC.
ZVRA
0001612084
Bode John B
C/O ZEVRA THERAPEUTICS, INC.
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION
FL
34747
1
0
Stock Option (right to buy)
4.97
2023-05-03
4
A
0
58800
0
A
2033-05-02
Common Stock
58800
58800
D
The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023.
This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.
33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer.
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode
2023-05-08